Sarah A. Hurvitz, MD, director of the Breast Oncology Program and medical director of the Clinical Research Unit at the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the current options for patients with HER2-positive metastatic breast cancer. She says it is an exciting time as there are many treatment options right now.
The standard of care in the frontline is trastuzumab, pertuzumab (Perjeta), and a taxane, with taxmen administered for 4 to 6 cycles before patients receive the maintenance of trastuzumab and pertuzumab. This is based on data from the CLEOPATRA study which demonstrated a significant improved in overall survival, according to Hurvitz.
Second-line standard of care for these patients is ado-trastuzumab emtansine (T-DM1; Kadcyla), an antibody-drug conjugate that targets HER2. This is based on findings from the EMILIA trial.
With these standards, there are little unanswered questions in the first- and second-line setting for these patients. After that, Hurvitz says there are multiple therapeutic options that can be used or myriad therapies that are being investigated in clinical trials now.
For more resources and information regarding anticancer targeted therapies in breast cancer: [ Ссылка ]
